169 related articles for article (PubMed ID: 28677794)
1. PRMT2β, a C-terminal splice variant of PRMT2, inhibits the growth of breast cancer cells.
Zhong J; Chen YJ; Chen L; Shen YY; Zhang QH; Yang J; Cao RX; Zu XY; Wen GB
Oncol Rep; 2017 Aug; 38(2):1303-1311. PubMed ID: 28677794
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma.
Zhong J; Cao RX; Zu XY; Hong T; Yang J; Liu L; Xiao XH; Ding WJ; Zhao Q; Liu JH; Wen GB
FEBS J; 2012 Jan; 279(2):316-35. PubMed ID: 22093364
[TBL] [Abstract][Full Text] [Related]
3. Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein.
Zhong J; Cao RX; Liu JH; Liu YB; Wang J; Liu LP; Chen YJ; Yang J; Zhang QH; Wu Y; Ding WJ; Hong T; Xiao XH; Zu XY; Wen GB
Oncogene; 2014 Nov; 33(48):5546-58. PubMed ID: 24292672
[TBL] [Abstract][Full Text] [Related]
4. Protein arginine methyltransferase 1 may be involved in pregnane x receptor-activated overexpression of multidrug resistance 1 gene during acquired multidrug resistant.
Li T; Kong AN; Ma Z; Liu H; Liu P; Xiao Y; Jiang X; Wang L
Oncotarget; 2016 Apr; 7(15):20236-48. PubMed ID: 26934120
[TBL] [Abstract][Full Text] [Related]
5. PRMT2 and RORγ expression are associated with breast cancer survival outcomes.
Oh TG; Bailey P; Dray E; Smith AG; Goode J; Eriksson N; Funder JW; Fuller PJ; Simpson ER; Tilley WD; Leedman PJ; Clarke CL; Grimmond S; Dowhan DH; Muscat GE
Mol Endocrinol; 2014 Jul; 28(7):1166-85. PubMed ID: 24911119
[TBL] [Abstract][Full Text] [Related]
6. Fangchinoline inhibits cell proliferation via Akt/GSK-3beta/ cyclin D1 signaling and induces apoptosis in MDA-MB-231 breast cancer cells.
Wang CD; Yuan CF; Bu YQ; Wu XM; Wan JY; Zhang L; Hu N; Liu XJ; Zu Y; Liu GL; Song FZ
Asian Pac J Cancer Prev; 2014; 15(2):769-73. PubMed ID: 24568493
[TBL] [Abstract][Full Text] [Related]
7. Identification and expression analysis of a novel transcript of the human PRMT2 gene resulted from alternative polyadenylation in breast cancer.
Zhong J; Cao RX; Hong T; Yang J; Zu XY; Xiao XH; Liu JH; Wen GB
Gene; 2011 Nov; 487(1):1-9. PubMed ID: 21820040
[TBL] [Abstract][Full Text] [Related]
8. BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR.
Hao L; ElShamy WM
Int J Cancer; 2007 Jul; 121(1):39-46. PubMed ID: 17278098
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.
Cohen B; Shimizu M; Izrailit J; Ng NF; Buchman Y; Pan JG; Dering J; Reedijk M
Breast Cancer Res Treat; 2010 Aug; 123(1):113-24. PubMed ID: 19915977
[TBL] [Abstract][Full Text] [Related]
10. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1.
Wulf GM; Ryo A; Wulf GG; Lee SW; Niu T; Petkova V; Lu KP
EMBO J; 2001 Jul; 20(13):3459-72. PubMed ID: 11432833
[TBL] [Abstract][Full Text] [Related]
11. Citron kinase (CIT-K) promotes aggressiveness and tumorigenesis of breast cancer cells in vitro and in vivo: preliminary study of the underlying mechanism.
Meng D; Yu Q; Feng L; Luo M; Shao S; Huang S; Wang G; Jing X; Tong Z; Zhao X; Liu R
Clin Transl Oncol; 2019 Jul; 21(7):910-923. PubMed ID: 30565087
[TBL] [Abstract][Full Text] [Related]
12. Methylation of C/EBPα by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer.
Liu LM; Sun WZ; Fan XZ; Xu YL; Cheng MB; Zhang Y
Cancer Res; 2019 Jun; 79(11):2865-2877. PubMed ID: 31015230
[TBL] [Abstract][Full Text] [Related]
13. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo.
Chen J; Zeng J; Xin M; Huang W; Chen X
Horm Metab Res; 2011 Sep; 43(10):681-6. PubMed ID: 21932171
[TBL] [Abstract][Full Text] [Related]
14. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F
Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194
[TBL] [Abstract][Full Text] [Related]
15. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
[TBL] [Abstract][Full Text] [Related]
16. RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway.
Zhang F; Wang Z; Yuan J; Wei X; Tian R; Niu R
Breast Cancer Res Treat; 2015 Sep; 153(2):263-75. PubMed ID: 26253946
[TBL] [Abstract][Full Text] [Related]
17. PRMT2 accelerates tumorigenesis of hepatocellular carcinoma by activating Bcl2 via histone H3R8 methylation.
Hu G; Yan C; Xie P; Cao Y; Shao J; Ge J
Exp Cell Res; 2020 Sep; 394(2):112152. PubMed ID: 32574605
[TBL] [Abstract][Full Text] [Related]
18. Α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling.
Zhuo RJ; Wang F; Zhang XH; Zhang JJ; Xu J; Dong W; Zou ZQ
Mol Med Rep; 2014 Mar; 9(3):993-8. PubMed ID: 24425042
[TBL] [Abstract][Full Text] [Related]
19. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
